Suppr超能文献

接受高风险经皮冠状动脉介入治疗患者的Impella 2.5循环支持持续时间及住院时间

The Duration of Impella 2.5 Circulatory Support and Length of Hospital Stay of Patients Undergoing High-risk Percutaneous Coronary Interventions.

作者信息

Anusionwu Obiora, Fischman Daniel, Cheriyath Pramil

机构信息

Department of Hospital Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, United States of America.

Department of Internal Medicine, Pinnacle Health Systems, Harrisburg, Pennsylvania 17104, United States of America.

出版信息

Cardiol Res. 2012 Aug;3(4):154-157. doi: 10.4021/cr190e. Epub 2012 Jul 20.

Abstract

BACKGROUND

To evaluate the impact of duration of Impella 2.5 support (Abiomed, Danvers, MA) on hospitalization of patients after high-risk percutaneous coronary intervention (PCI). There has been a continuous increase in prevalence of coronary artery disease with more patients needing PCI during acute myocardial infarction. Some of these patients have to undergo high-risk revascularization with circulatory support like the Impella 2.5 device.

METHODS

This study was a single center retrospective study of patients admitted to our hospital who required Impella circulatory support during percutaneous coronary intervention. Patients' medical records, cardiac catheterization laboratory and 2-D echocardiography reports were reviewed to ascertain left ventricular ejection fraction, duration of Impella support, Coronary Care Unit (CCU) days and the length of stay in the hospital. A P-value of ≤ 0.05 was considered statistically significant.

RESULTS

Over a 15-month period, we had 25 patients with 19 males and 6 females. Mean age of the patient cohort was 68 ± 10 years. Mean LVEF of the group was 32 ± 16%. Mean length of hospital stay was 8 ± 8 days and mean CCU stay was 4 ± 4 days. The Impella was successfully inserted in all cases with a median duration of support of 70 minutes (range, 4 - 5760 minutes). Bleeding complication occurred in 8%. Spearman's rank correlation coefficient between the duration of Impella support and hospital stay was 0.49 (P = 0.023) while it was 0.71 (P = 0.001) between Impella support duration and CCU days.

CONCLUSIONS

Our study suggests that there is a positive correlation between the duration of Impella 2.5 circulatory support and hospital stay and/or CCU days. The correlation seems to be stronger with CCU days.

摘要

背景

评估Impella 2.5支持装置(美国马萨诸塞州丹弗斯市的Abiomed公司生产)的支持时长对高危经皮冠状动脉介入治疗(PCI)术后患者住院情况的影响。冠状动脉疾病的患病率持续上升,急性心肌梗死期间需要进行PCI的患者越来越多。其中一些患者必须借助Impella 2.5装置等循环支持手段接受高危血运重建治疗。

方法

本研究是一项单中心回顾性研究,纳入了我院接受经皮冠状动脉介入治疗期间需要Impella循环支持的患者。查阅患者的病历、心导管检查实验室报告和二维超声心动图报告,以确定左心室射血分数、Impella支持时长、冠心病监护病房(CCU)住院天数和住院时长。P值≤0.05被认为具有统计学意义。

结果

在15个月的时间里,我们共纳入了25例患者,其中男性19例,女性6例。患者队列的平均年龄为68±10岁。该组的平均左心室射血分数为32±16%。平均住院时长为8±8天,平均CCU住院时长为4±4天。所有病例中Impella均成功植入,支持时长的中位数为70分钟(范围为4 - 5760分钟)。出血并发症发生率为8%。Impella支持时长与住院时长之间的Spearman等级相关系数为0.49(P = 0.023),而Impella支持时长与CCU住院天数之间的相关系数为0.71(P = 0.001)。

结论

我们的研究表明,Impella 2.5循环支持时长与住院时长和/或CCU住院天数之间存在正相关。这种相关性在CCU住院天数方面似乎更强。

相似文献

4
Percutaneous retrograde left ventricular assist support for interventions in patients with aortic stenosis and left ventricular dysfunction.
Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1201-9. doi: 10.1002/ccd.24303. Epub 2012 Apr 17.
5
Real-world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry.
Catheter Cardiovasc Interv. 2017 Oct 1;90(4):576-581. doi: 10.1002/ccd.26979. Epub 2017 Apr 18.
9
Complex High-Risk Indicated Percutaneous Coronary Intervention With Prophylactic Use of the Impella CP Ventricular Assist Device.
J Invasive Cardiol. 2022 Sep;34(9):E665-E671. doi: 10.25270/jic/22.00031. Epub 2022 Aug 19.

引用本文的文献

1
A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention.
Heart Int. 2020 Dec 29;14(2):92-99. doi: 10.17925/HI.2020.14.2.92. eCollection 2020.
2
Percutaneous Ventricular Assist Devices: A Health Technology Assessment.
Ont Health Technol Assess Ser. 2017 Feb 7;17(2):1-97. eCollection 2017.

本文引用的文献

1
Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella Registry.
Catheter Cardiovasc Interv. 2012 Nov 1;80(5):717-25. doi: 10.1002/ccd.23403. Epub 2012 Apr 25.
2
What is high-risk PCI, and how do you safely perform it?
J Invasive Cardiol. 2011 Oct;23(10):425-6.
3
Use of the Impella 2.5 for prophylactic circulatory support during elective high-risk percutaneous coronary intervention.
Cardiovasc Revasc Med. 2011 Sep-Oct;12(5):299-303. doi: 10.1016/j.carrev.2011.02.002. Epub 2011 Mar 30.
4
Use of the Impella 2.5 in high-risk percutaneous coronary intervention.
Crit Care Nurse. 2011 Feb;31(1):e1-16. doi: 10.4037/ccn2011293.
5
Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry.
J Am Coll Cardiol. 2009 Dec 15;54(25):2430-4. doi: 10.1016/j.jacc.2009.09.018.
9
Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study.
J Cardiovasc Med (Hagerstown). 2008 Oct;9(10):1004-10. doi: 10.2459/JCM.0b013e3282f9abe7.
10
Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics.
Catheter Cardiovasc Interv. 2007 Oct 1;70(4):532-7. doi: 10.1002/ccd.21160.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验